2015


To access this material please log in or register

Register Authorize
2015/№4

The study X–VERT: modern anticoagulant therapy during cardioversion in patients with atrial fibrillation

Kanorsky S. G.
State Budgetary Educational Institution of Higher Professional Education, "Kuban State Medical University" of the RF Ministry of Health Care, Sedina 4, Krasnodar 350063

Keywords: cardioversion, oral anticoagulant, stroke, thromboembolism

DOI: 10.18087/rhj.2015.4.2108

The study X–VeRT is the first prospective, randomized study of a new oral anticoagulant. The study was performed on 1504 patients with atrial fibrillation (AF) who have undergone early or delayed cardioversion. Primary efficacy endpoint was the total number of cases of stroke, transient ischemic attack, peripheral artery embolism, MI, and cardiovascular death; primary safety endpoint was a major bleeding. Primary efficacy endpoint events were observed in 0.51% of patients in the rivaroxaban treatment group and in 1.02% of patients in the vitamin K antagonist (VKA) treatment group. The rivaroxaban treatment significantly decreased the time to cardioversion compared with the VKA treatment group (p<0.001). Major bleedings were observed in 0.6% of patients in the rivaroxaban treatment group and 0.8% of patients in the VKA treatment group. Only rivaroxaban has methodically based and clinically studied regimens of treatment in early and delayed cardioversion for patients with AF duration of >48 h or unknown duration.
  1. Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY, Davies MK. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace. 2012 Nov;14 (11):1553–9.
  2. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013 Apr;15 (4):486–93.
  3. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009 Dec 1;104 (11):1534–9.
  4. Reardon G, Nelson WW, Patel AA, Philpot T, Neidecker M. Prevalence of atrial fibrillation in US nursing homes: results from the national nursing home survey, 1985–2004. J Am Med Dir Assoc. 2012 Jul;13 (6):529–34.
  5. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013 Sep 1;167 (5):1807–24.
  6. Nattel S, Guasch E, Savelieva I, Cosio FG, Valverde I, Halperin JL et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J. 2014 Jun 7;35 (22):1448–56.
  7. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr et al. 2014 AHA / ACC / HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64 (21):e1‑e76.
  8. Coll-Vinent B, Fuenzalida C, García A, Martin A, Miro O. Management of acute atrial fibrillation in the emergency department: a systematic review of recent studies. Eur J Emerg Med. 2013 Jun;20 (3):151–9.
  9. Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, Hartikanen JE. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV Study. J Am Coll Cardiol. 2013 Sep 24;62 (13):1187–92.
  10. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998 Dec 15;82 (12):1545–7, A8.
  11. Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2015 Jan;17 (1):18–23.
  12. Канорский С. Г., Зингилевский К. Б., Мироненко М. Ю. Значение чреспищеводной эхокардиографии для определения тактики купирования фибрилляции предсердий. Кардиология. 2002;42 (1):86–90.
  13. Канорский С. Г., Зингилевский К. Б., Мироненко М. Ю. Восста­новление функции левого предсердия после кардиоверсии мерцательной аритмии: роль некоторых клинических и эхокардиографических факторов. Кардиология. 2002;42 (2):54–8.
  14. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the mana­gement of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33 (21):2719–47.
  15. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014 Oct;30 (10):1114–30.
  16. Диагностика и лечение фибрилляции предсердий. Российский кардиологический журнал. 2013;4 (102):1–100. Приложение 3.
  17. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011 Jan 18;123 (2):131–6.
  18. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013 May 14;61 (19):1998–2006.
  19. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014 Mar 25;63 (11):1082–7.
  20. Yadlapati A, Groh C, Passman R. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol. 2014 Apr 15;113 (8):1362–3.
  21. Caldeira D, Costa J, Ferreira JJ, Lip GY, Pinto FJ. Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clin Res Cardiol. 2015 Jul;104 (7):582–90.
  22. Лукьянов М. М., Бойцов С. А., Якушин C. С., Марцевич С. Ю., Воробьёв А. Н., Загребельный А. В. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным РЕгистра КардиоВАскулярных ЗАболеваний РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии. 2014;10 (4):366–77.
  23. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365 (10):883–91.
  24. Diamantopoulos A, Forster F, Evers Th. Real-life treatment persistence with newer oral anticoagulants and potential strokes avoided in patients with atrial fibrillation. ESC Congress 2013: poster P519.
  25. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014 Dec 14;35 (47):3346–55.
  26. Ezekowitz MD, Cappato R, Klein AL, Camm AJ, Ma CS, Le Heuzey JY et al. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of cardiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: a comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. Am Heart J. 2014 May;167 (5):646–52.
  27. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010 Jan;8 (1):202–4.
  28. Silverman DI, Manning WJ. Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation. Circulation. 1998 Aug 4;98 (5):479–86.
  29. Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol. 1989 Mar 15;63 (11):745–6.
  30. Di Biase L, Burkhardt JD, Gilbert G, Santangeli P, Santoro F, Sanchez J et al. Dabigratan has a higher risk of left atrial appendage thrombus formation in patients with AF when compared to warfarin and rivaroxaban. Circulation. 2013;128: A14308.
Kanorsky S. G. The study X–V ERT: modern anticoagulant therapy during cardioversion in patients with atrial fibrillation. Russian Heart Journal. 2015;14 (4):248–255

To access this material please log in or register

Register Authorize
Ru En